Cardlytics, Inc. (NASDAQ:CDLX – Get Free Report) insider Nicholas Hollmeyer Lynton sold 6,464 shares of the business’s stock in a transaction dated Friday, January 3rd. The shares were sold at an average price of $3.67, for a total value of $23,722.88. Following the transaction, the insider now owns 91,771 shares in the company, valued at approximately $336,799.57. This represents a 6.58 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
Cardlytics Stock Performance
Shares of CDLX stock opened at $3.35 on Thursday. The company’s fifty day moving average price is $3.89 and its 200-day moving average price is $4.77. The stock has a market cap of $170.25 million, a PE ratio of -0.55 and a beta of 1.53. The company has a current ratio of 1.18, a quick ratio of 1.18 and a debt-to-equity ratio of 2.40. Cardlytics, Inc. has a 12 month low of $2.89 and a 12 month high of $20.52.
Cardlytics (NASDAQ:CDLX – Get Free Report) last announced its earnings results on Wednesday, November 6th. The company reported ($0.15) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.18. Cardlytics had a negative net margin of 93.55% and a negative return on equity of 110.67%. The business had revenue of $67.06 million during the quarter, compared to the consensus estimate of $57.77 million. During the same quarter last year, the firm earned ($0.26) earnings per share. The business’s revenue for the quarter was down 15.1% on a year-over-year basis. On average, equities analysts expect that Cardlytics, Inc. will post -1.52 EPS for the current fiscal year.
Wall Street Analyst Weigh In
Read Our Latest Stock Analysis on CDLX
Institutional Inflows and Outflows
A number of large investors have recently added to or reduced their stakes in CDLX. Bank of New York Mellon Corp raised its position in shares of Cardlytics by 15.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 135,924 shares of the company’s stock worth $1,116,000 after purchasing an additional 18,179 shares during the last quarter. Quest Partners LLC lifted its stake in shares of Cardlytics by 160.4% in the second quarter. Quest Partners LLC now owns 17,956 shares of the company’s stock worth $147,000 after buying an additional 11,061 shares in the last quarter. ClariVest Asset Management LLC grew its holdings in shares of Cardlytics by 48.7% during the second quarter. ClariVest Asset Management LLC now owns 72,546 shares of the company’s stock valued at $596,000 after buying an additional 23,746 shares during the last quarter. Renaissance Technologies LLC increased its position in shares of Cardlytics by 711.9% during the second quarter. Renaissance Technologies LLC now owns 351,035 shares of the company’s stock valued at $2,882,000 after acquiring an additional 307,800 shares in the last quarter. Finally, Pekin Hardy Strauss Inc. purchased a new position in Cardlytics in the 2nd quarter worth approximately $243,000. Hedge funds and other institutional investors own 68.10% of the company’s stock.
About Cardlytics
Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.
Featured Stories
- Five stocks we like better than Cardlytics
- Energy and Oil Stocks Explained
- Moderna Shares Spike on H5N1 News—What’s Next for Investors?
- Most active stocks: Dollar volume vs share volume
- Nebius Group (NBIS): A Small-Cap Backed by NVIDIA
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- Natural Gas Demand to Surge: Top 3 Stocks and ETFs to Consider
Receive News & Ratings for Cardlytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardlytics and related companies with MarketBeat.com's FREE daily email newsletter.